{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-238295","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2023-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.080851+00:00","generated_at":"2026-06-10T12:13:30.869632+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inhibikase provides pipeline updates after sharp stock decline; 201 Trial enrollment at 28 patients","bullets":["Stock dropped dramatically over last 8 trading sessions; no identifiable cause for volatility.","Risvodetinib 201 Trial: 28 of 120 patients enrolled/screening; one completed 12-week dosing; portal added 50 potential participants in Sept.","Safety data for risvodetinib presented on 119 people at MDS Congress; no side effects of clinical significance.","IkT-001Pro: FDA meeting request steps completed; bioequivalence study to 600 mg imatinib mesylate due early Q4 2023.","Cash position sufficient to fund operations into Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-238295","json":"https://secwatch.observer/filing/0001193125-23-238295.json","markdown":"https://secwatch.observer/filing/0001193125-23-238295.md","text":"https://secwatch.observer/filing/0001193125-23-238295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523238295/0001193125-23-238295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523238295/d509876d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T12:13:30.869632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}